These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 17083508)

  • 1. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches.
    Coppola A; Di Minno MN; Santagostino E
    Br J Haematol; 2010 Sep; 150(5):515-28. PubMed ID: 20573153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J; Morado M; Rocino A; van den Berg HM; von Depka M; Gringeri A; Mantovani L; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab as a single agent in the management of adult patients with haemophilia A and inhibitors: marked reduction in inhibitor level and clinical improvement in bleeding but failure to eradicate the inhibitor.
    Aleem A; Saidu A; Abdulkarim H; Al-Diab AR; Al-Sagheer A; Qayum A; Al-Momen AK
    Haemophilia; 2009 Jan; 15(1):210-6. PubMed ID: 19149851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
    Di Minno G; Coppola A
    Haemophilia; 2013 Jan; 19 Suppl 1():18-23. PubMed ID: 23278996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat inhibitors in haemophilia.
    Makris M; Hay CR; Gringeri A; D'Oiron R
    Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis in haemophilia patients with inhibitors.
    Leissinger CA
    Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
    Leissinger CA
    Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of VWF for the success of immune tolerance induction.
    Kreuz W
    Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.